SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA's approval for Hydrocortisone Valerate Cream

16 Aug 2019 Evaluate

Lupin has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (USFDA). Hydrocortisone Valerate Cream USP, 0.2% had an annual sales of approximately $15 million in the US (IQVIA MAT March 2019).

The company’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic version of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries, Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2328.70 4.45 (0.19%)
20-Apr-2026 11:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.15
Dr. Reddys Lab 1236.65
Cipla 1236.45
Zydus Lifesciences 938.75
Lupin 2328.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×